SciSparc to Sell Stake in MitoCareX

Ticker: SPRC · Form: 6-K · Filed: Sep 26, 2024 · CIK: 1611746

Scisparc Ltd. 6-K Filing Summary
FieldDetail
CompanyScisparc Ltd. (SPRC)
Form Type6-K
Filed DateSep 26, 2024
Risk Levelmedium
Pages1
Reading Time1 min
Sentimentneutral

Sentiment: neutral

Topics: divestiture, letter-of-intent, strategic-shift

TL;DR

SciSparc LOI to sell MitoCareX stake - details TBD.

AI Summary

On September 26, 2024, SciSparc Ltd. announced it has signed a non-binding Letter of Intent to sell its stake in MitoCareX. The specific details of the stake and the financial terms of the potential sale were not disclosed in this filing.

Why It Matters

This potential divestiture could signal a strategic shift for SciSparc, impacting its future focus and financial structure.

Risk Assessment

Risk Level: medium — The filing is a non-binding letter of intent, meaning the transaction is not guaranteed and details are still to be determined.

Key Players & Entities

  • SciSparc Ltd. (company) — Filer of the report and potential seller
  • MitoCareX (company) — Company in which SciSparc intends to sell a stake

FAQ

What is the nature of the non-binding Letter of Intent?

The filing states that SciSparc Ltd. has signed a non-binding Letter of Intent to sell its stake in MitoCareX.

When was this Letter of Intent announced?

The Letter of Intent was announced on September 26, 2024.

What is the specific stake SciSparc intends to sell in MitoCareX?

The filing does not specify the exact percentage or nature of the stake SciSparc intends to sell in MitoCareX.

Are the financial terms of the potential sale disclosed?

No, the filing indicates that the Letter of Intent is non-binding and does not disclose specific financial terms.

What is the filing form type?

This is a Form 6-K report.

Filing Stats: 312 words · 1 min read · ~1 pages · Grade level 9.9 · Accepted 2024-09-26 09:21:43

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. SciSparc Ltd. Date: September 26, 2024 By: /s/ Oz Adler Name: Oz Adler Title: Chief Executive Officer and Chief Financial Officer 3

View Full Filing

View this 6-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.